Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The conference is scheduled for June 15-16, 2026, with the fireside chat available on demand beginning June 15 at 7:00 a.m. EDT.
The announcement underscores Helus Pharma's commitment to advancing its pipeline of proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the significant unmet need in mental health, particularly for individuals suffering from depression, anxiety, and other conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The participation of Inamdar in the H.C. Wainwright conference provides an opportunity for investors and industry stakeholders to gain insights into the company's clinical programs and strategic direction. The fireside chat format allows for in-depth discussion on the potential of NSAs to transform mental health treatment.
For more information about Helus Pharma and its developments, the full press release is available at https://ibn.fm/KsnJW. Company updates can also be found on its website at www.helus.com.
